In March 2013, we published a study in JAMA Psychiatry assessing the prevalence of anti-N-methyl-D-aspartate glutamate receptor (NMDAR) serum autoantibodies in unmedicated acutely ill patients with schizophrenia, major depression (MD), borderline personality disorder (BLPD), and healthy control individuals without neuropsychiatric disorder. 1 The laboratory analyses of this set of samples were done in 2010. N-methyl-Daspartate glutamate receptor antibodies were identified in 15 patients, primarily in those with a clinical diagnosis of schizophrenia (12 of 121, 9.9%) as opposed to those with MD (2 of 70, 2.9%), those with BLPD (0 of 38, 0%), and control individuals (1 of 230, 0.4%). Two patients were initially misdiagnosed as having catatonic or disorganized schizophrenia. Retrospectively, these cases were reclassified as cases with NMDAR encephalitis (presence of specific IgG anti-NR1a autoantibodies in both serum and cerebrospinal fluid). Discussion | Using up-to-date commercial assays, IgA, IgG, and IgM NR1a anti-NMDAR autoantibodies showed a broader distribution than previously assumed and can be detected in the peripheral blood of a considerable percentage of healthy control individuals. 2 Notably, low IgG anti-NR1a autoantibody titers (1:10 and 1:32) have been observed in 2 healthy individuals from our retest sample. These antibodies were previously believed to be 100% specific for NMDAR encephalitis. 3 However, in line with recent observations of antibodies found in lupus erythematosus (antinuclear antibodies) or type 1 diabetes mellitus (islet cell and insulin antibodies), low serum autoantibody titers can be present in a considerable percentage of healthy people, while constantly higher autoantibody titers predispose to the clinical manifestation of an autoimmune disorder. 4, 5 Future research is needed to define a cutoff threshold for NMDAR autoantibody titers. Notably, this threshold may vary depending on the test systems applied. For instance, CBAs using fixed cells (eg, EUROIMMUN BIOCHIP assay system) appear to be more sensitive than CBAs using live transfected human embryonic kidney cells. 6 On the other hand, fixed cells do not have intact neuronal cell surfaces. Therefore, the NMDAR autoantibody binding seen in these cells could be less specifically targeted against cell surface epitopes of the NMDAR (intracellular epitopes may be detected).
Methods
Based on previous publications, we assumed that the presence of disorganized or catatonic symptoms in young female psychiatric patients should be considered as an alarm signal to think of NMDAR encephalitis as differential diagnosis, particularly when patients do not respond sufficiently to neuroleptic medication. 1, 7 However, blood IgA, IgG, or IgM NR1a anti-NMDAR autoantibody titers do not per se justify the diagnosis of NMDAR encephalitis and the initiation of immunosuppressive treatment. An interplay of several factors, such as bloodbrain barrier integrity and immunological activity, is apparently crucial for the development of central nervous system pathology and the consecutive emergence of mental illness in anti-NMDAR-seropositive cases. 2 Accordingly, data from patients with NMDAR encephalitis suggest that cerebrospinal fluid anti-NMDAR autoantibody titers show a much better correlation with clinical symptoms than blood autoantibody titers. 1, 3, 6 
